New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
19:16 EDTWTW, GSK, ARNA, PHMD, LCAV, CRAY, LOGM, CLF, Z, VSI, A, TRLA, GNC, NNAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Cliffs Natural (CLF), up 6.4% after reporting better-than-expected earnings and announcing it promoted Gary Halverson, formerly its president and COO, to president and CEO... LogMeln (LOGM), up 16%... Cray (CRAY), up 9.7%. ALSO HIGHER: LCA Vision (LCAV), up 29% after announcing an agreement to be acquired by PhotoMedex (PHMD) for $5.37 per share. Shares of PhotoMedex were little changed following the announcement... Arena Pharmaceuticals (ARNA), up 1.8% after the Daily Mail said GlaxoSmithKline (GSK) could be interested in a deal for the company. DOWN AFTER EARNINGS: Weight Watchers (WTW), down 20% after fourth quarter profit missed expectations and the company sharply cut its fiscal 2014 earnings outlook... GNC Holdings (GNC), down 15.7%... Trulia (TRLA), down 15.2%... Agilent (A), down 6%. ALSO LOWER: Vitamin Shoppe (VSI), down 8.5% after its vitamin retailing peer GNC reported disappointing fourth quarter sales and cut its fiscal 2014 outlook... Zillow (Z), down 3% after online real estate peer Trulia's quarterly report disappointed... Navios Maritime Acquisition (NNA), down 8.4% after filing to sell 12M shares of common stock.
News For WTW;GNC;TRLA;A;VSI;Z;CLF;LOGM;CRAY;LCAV;PHMD;ARNA;GSK;NNA From The Last 14 Days
Check below for free stories on WTW;GNC;TRLA;A;VSI;Z;CLF;LOGM;CRAY;LCAV;PHMD;ARNA;GSK;NNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
July 21, 2014
07:11 EDTGSKInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:19 EDTVSIVitamin Shoppe recommended ahead of Q2 report at Goldman
Goldman believes Vitamin Shoppe (VSI) competitive pressures are overblown and that the company has relatively low overlap with GNC (GNC) and that recent price cuts have had minimal impact. The firm expects Vitamin Shoppe's Q2 to mark the beginning of sharp earnings acceleration and better execution and recommends buying shares ahead of the Q2 report. Shares are rated Conviction Buy with a $60 price target.
July 18, 2014
12:48 EDTTRLA, ZRealPage tumbles after reporting preliminary Q2 revenue miss
Subscribe for More Information
10:05 EDTCLFCasablanca calls Cliffs Natural revised proxy 'desperate ploy'
Subscribe for More Information
08:15 EDTCLFCliffs Natural announces revised proxy with ISS, Glass Lewis recommendations
Cliffs Natural announced that it has revised its WHITE proxy card to provide shareholders with a clear path to vote consistently with the recommendations of Institutional Shareholder Services, or ISS, and Glass Lewis without inadvertently providing Casablanca Capital with a majority of the board as a result of Cliffs' cumulative voting provision. While both proxy solicitation firms have recommended shareholders support four Casablanca nominees, they have recommended that Cliffs' nominees should remain as the majority of Cliffs' board. As such, Cliffs' board has reduced its slate of directors to be elected at the 2014 Annual Meeting from nine to seven candidates, with Barry J. Eldridge and Stephen M. Johnson no longer standing for re-election. With this change, shareholders can vote the company's WHITE proxy card in order to elect four of Casablanca's nominees and seven of Cliffs' nominees, which is in line with both ISS' and Glass Lewis' recommendations. In addition, Cliffs' board is offering to include Lourenco Goncalves, Joseph Rutkowski, Gabriel Stoliar, and Douglas Taylor on Cliffs' WHITE proxy card, subject to such individuals providing Cliffs with their consent to include their names on Cliffs' proxy card.
July 17, 2014
10:12 EDTVSI, GNCGNC drops after analyst downgrades on sales concerns
Subscribe for More Information
10:00 EDTGNCOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 21st Century Fox (FOXA) downgraded to Buy from Strong Buy at ISI Group... Charter (CHTR) downgraded to Hold from Buy at Jefferies... Covidien (COV) downgraded to Hold from Buy at Needham... Diageo (DEO) downgraded to Underweight from Neutral at JPMorgan... GNC Holdings (GNC) downgraded to Hold from Buy at Jefferies... International Game (IGT) downgraded to Market Perform from Outperform at BMO Capital... JAVELIN Mortgage (JMI) downgraded to Market Perform from Outperform at JMP Securities... Macquarie Group (MQBKY) downgraded to Underweight from Neutral at JPMorgan... PNC Financial (PNC) downgraded to Neutral from Buy at Compass Point... PetSmart (PETM) downgraded to Sector Perform from Outperform at RBC Capital... Rexam (REXMY) downgraded to Hold from Buy at Deutsche Bank.
09:50 EDTCLFEgan-Jones recommends Cliffs Natural investors vote for director nominees
Subscribe for More Information
07:18 EDTGSKMylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information
07:16 EDTGNCGNC Holdings downgraded to Hold from Buy at Jefferies
Jefferies downgraded GNC Holdings to Hold citing a slowdown in industry sales trends and risk of near-term earnings disappointments. The firm lowered its price target for shares to $39 from $50.
06:23 EDTGSKGlaxoSmithKline admits to bribing Chinese officials in 2001, FT reports
Subscribe for More Information
06:20 EDTAAgilent initiated with a Neutral at Citigroup
Target $64.
05:30 EDTGNCGNC Holdings downgraded to Hold from Buy at Jefferies
Subscribe for More Information
05:13 EDTCLFISS, Glass Lewis recommend Cliffs Natural holders vote GOLD proxy card
Subscribe for More Information
July 16, 2014
16:33 EDTZZillow acquires Retsly
Zillow announced it has acquired Vancouver, BC based Retsly, a software company that normalizes real estate data from multiple listing services so developers can build data-driven products for the real estate industry. The company also provides MLSs with the tools to manage software applications in their market and ensure their content is being used appropriately. Zillow is not disclosing the financial terms of the acquisition. "Retsly's platform will spur tremendous innovation in the real estate space, enabling developers to build software that works across MLS boundaries and without the overhead of dealing with local data formats," said Spencer Rascoff, Zillow CEO. "Retsly's team and cutting-edge technology is a great fit with Zillow and aligns with our goal to offer great value and services to our industry partners. We're thrilled to welcome Retsly to Zillow." Retsly was founded in 2013 and will continue to operate from Vancouver.
09:37 EDTARNAActive equity options trading on open
Subscribe for More Information
07:24 EDTZSiemer & Associates to hold a summit
Subscribe for More Information
07:14 EDTGSKIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
05:48 EDTCRAYCray awarded contract to install India's first Cray XC30 Supercomputer
Subscribe for More Information
05:38 EDTGSKGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use